Galantamine-Memantine Combination as an Antioxidant Treatment for Schizophrenia

Maju Mathew Koola, Samir Kumar Praharaj, Anilkumar Pillai

Research output: Contribution to journalReview articlepeer-review

15 Scopus citations


Purpose of Review: The objective of this article is to highlight the potential role of the galantamine-memantine combination as a novel antioxidant treatment for schizophrenia. Recent Findings: In addition to the well-known mechanisms of action of galantamine and memantine, these medications also have antioxidant activity. Furthermore, an interplay exists between oxidative stress, inflammation (redox-inflammatory hypothesis), and kynurenine pathway metabolites. Also, there is an interaction between brain-derived neurotrophic factor and oxidative stress in schizophrenia. Oxidative stress may be associated with positive, cognitive, and negative symptoms and impairments in white matter integrity in schizophrenia. The antipsychotic-galantamine-memantine combination may provide a novel strategy in schizophrenia to treat positive, cognitive, and negative symptoms. Summary: A “single antioxidant” may be inadequate to counteract the complex cascade of oxidative stress. The galantamine-memantine combination as “double antioxidants” is promising. Hence, randomized controlled trials are warranted with the antipsychotic-galantamine-memantine combination with oxidative stress and antioxidant biomarkers in schizophrenia.

Original languageEnglish (US)
Pages (from-to)37-50
Number of pages14
JournalCurrent Behavioral Neuroscience Reports
Issue number2
StatePublished - Jun 15 2019
Externally publishedYes


  • Antioxidant
  • Clinical high risk
  • Galantamine
  • Memantine
  • Oxidative stress
  • Schizophrenia

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Behavioral Neuroscience


Dive into the research topics of 'Galantamine-Memantine Combination as an Antioxidant Treatment for Schizophrenia'. Together they form a unique fingerprint.

Cite this